<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01067443</url>
  </required_header>
  <id_info>
    <org_study_id>LEAP 0208</org_study_id>
    <nct_id>NCT01067443</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa</brief_title>
  <official_title>A Phase II Randomized, Parallel Arm, Open-labeled Clinical Trial to Assess the Safety and Efficacy of the Combination of Sodium Stibogluconate Plus Single Dose AmBisome®, Miltefosine Plus Single Dose AmBisome® and Miltefosine Alone for the Treatment of Primary Visceral Leishmaniasis in Eastern Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drugs for Neglected Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paladin Laboratories Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Drugs for Neglected Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess if shorter combinations of SSG plus single dose AmBisome®,
      Miltefosine plus single dose AmBisome® and Miltefosine alone are effective in treating
      visceral leishmaniasis in Eastern Africa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study intends to look at potential feasible short course combination therapies as
      well as evaluate (and possibly register) miltefosine in its conventional dose against VL in
      Sudan and Kenya.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Initial cure: proportion cured at Day 28</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Final cure: proportion cured at day 210</measure>
    <time_frame>6 months post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and serious adverse events occurring in the three study arms</measure>
    <time_frame>up to day 60</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Primary Visceral Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>Amb+SSG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amb+Milt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Milt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal amphotericin B (AmBisome®) and sodium stibogluconate</intervention_name>
    <description>AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11</description>
    <arm_group_label>Amb+SSG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal amphotericin B + miltefosine</intervention_name>
    <description>AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11</description>
    <arm_group_label>Amb+Milt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miltefosine</intervention_name>
    <description>Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28</description>
    <arm_group_label>Milt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinical signs and symptoms of VL and diagnosis confirmed by
             visualization of parasites in tissue samples (lymph node, bone marrow or spleen where
             relevant) on microscopy.

          -  Patients aged between 7 (to allow for blood sampling) and 60 years (inclusive) who are
             able to comply with the protocol.

          -  Patients for whom written informed consent has been signed by the patients themselves
             (if aged 18 years and over) or by parents(s) or legal guardian for patients under 18
             years of age.

          -  HIV negative status

        Exclusion Criteria:

          -  Patients who have received any anti-leishmanial drugs in the last 6 months/ relapse
             cases.

          -  Patients with a negative lymph node/bone marrow (or spleen) smears.

          -  Patients with severe protein and or caloric malnutrition (Kwashiorkor or marasmus ;
             Adults: BMI &lt;/= 15, Children W/H&lt;70, presence of oedema)

          -  Patients with previous history of hypersensitivity reaction to SSG or Amphotericin B.

          -  Patients suffering from a concomitant severe infection such as TB or any other serious
             underlying disease (cardiac, renal, hepatic) which would preclude evaluation of the
             patient's response to study medication.

          -  Patients suffering from other conditions associated with splenomegaly such as
             schistosomiasis.

          -  Patients with previous history of cardiac arrhythmia or an abnormal ECG

          -  Patients who are female of child bearing age (all females who have achieved menarche)
             / pregnant or lactating.

          -  Patients with haemoglobin &lt; 5gm/dl.

          -  Patients with WBC &lt; 1 x 10³/mm³.

          -  Patients with platelets &lt; 40,000/mm³.

          -  Patients with abnormal liver function (ALT and AST) tests of more than three times the
             normal range.

          -  Patients with serum creatinine outside the normal range for age and gender.

          -  Major surgical intervention within 2 weeks prior to enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monique Wasunna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kenya Medical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kimalel Health Centre</name>
      <address>
        <city>Kimalel</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kassab Hospital</name>
      <address>
        <city>Kassab</city>
        <state>Gedaref</state>
        <country>Sudan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Hassan Centre for Tropical Medicine</name>
      <address>
        <city>Doka</city>
        <state>Gedarif</state>
        <country>Sudan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Sudan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2010</study_first_submitted>
  <study_first_submitted_qc>February 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2010</study_first_posted>
  <last_update_submitted>April 21, 2017</last_update_submitted>
  <last_update_submitted_qc>April 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase II</keyword>
  <keyword>Randomised clinical trial</keyword>
  <keyword>Visceral Leishmaniasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Visceral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Miltefosine</mesh_term>
    <mesh_term>Antimony Sodium Gluconate</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://journals.plos.org/plosntds/article/file?type=supplementary&amp;id=info:doi/10.1371/journal.pntd.0004880.s002</doc_url>
      <doc_comment>Final Study Protocol</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

